Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Source: Eur Respir J 2004; 23: 832-840 Year: 2004
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Source: Eur Respir J 2004; 23: 241-249 Year: 2004
Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 86-94 Year: 2004
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Respiratory muscles‘ function in chronic obstructive pulmonary disease patients treted with anticholinergic bronchodilator Source: Annual Congress 2009 - Respiratory physiology Year: 2009
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004
The effect of tiotropium on exacerbations and airflow in patients with COPD Source: Eur Respir J 2006; 27: 547-555 Year: 2006
Exercise and dyspnoea in COPD Source: Eur Respir Rev 2006; 15: 72-79 Year: 2006
Tiotropium as essential maintenance therapy in COPD Source: Eur Respir Rev 2006; 15: 51-57 Year: 2006
A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002